Dr Toon Van Gorp: Mirvetuximab Soravtansine Should Be Global Standard for FRα+ Ovarian Cancer

In part 2 of an interview with The American Journal of Managed Care^®, Toon Van Gorp, MD, PhD, professor of gynecologic oncology at the University of Leuven, delves deeper into the phase 3 MIRASOL trial (NCT04209855) final analysis, highlighting the efficacy of mirvetuximab soravtansine-gynx (Elahere; AbbVie) in patients with folate receptor alpha-positive (FRα+), platinum-resistant ovarian cancer.

He also discusses how these findings could influence future treatment guidelines, emphasizing that mirvetuximab soravtansine should be "the new standard of care all over the world."

Van Gorp, a MIRASOL trial investigator, presented these findings in a late-breaking session at the Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer on Saturday. Watch part 1 of the interview to explore the similarities between the primary and final analyses of the trial.

This transcript has been lightly edited for clarity; captions were auto-generated.

Transcript

How do the final MIRASOL results reinforce the efficacy of mirvetuximab soravtansine in patients with FRα+, platinum-resistant ovarian cancer?

I think it's very important to realize that this is one of the longest follow-up times that we have ever seen in any of the platinum-resistant ovarian cancer studies. Usually, we don't see any benefit for the experimental arm in platinum-resistant ovarian cancer, but this is one of the first studies in which we saw a benefit and it is maintained for a very long time. I think, in my opinion, this means that mirvetuximab is really to be considered the standard of care for FRα+, platinum-resistant ovarian cancer.

The second thing is that it's also very important that we include FRα testing in our standard of care so that we do this from the start, when we have the first diagnosis, or when the patient is first diagnosed with platinum-resistant ovarian cancer, because I think it's really necessary for our patients to receive this treatment.

How might these findings influence treatment guidelines and the standard of care for this population?

In the US, the FDA already approved it, and it is already in the NCCN [National Comprehensive Cancer Network] guidelines. In Europe, we had to wait a little bit longer for approval, but I really hope that mirvetuximab will now be in the future guidelines for platinum-resistant ovarian cancers.

There is no doubt in my head that this will be the new standard of care all over the world. These results only reinforce the position of mirvetuximab in the platinum-resistant setting.